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The elongation step is involved in the regulation of protein synthesis during the cell cycle, environmental stress, ageing and transformation. Using 
a diphtheria toxin-mediated assay for measuring the levels of ADP-ribosylatable elongation factor EF-2, we have observed an irreversible decrease 
of up to 64% in the amount of ADP-ribosylatable EF-2 in normal diploid human fibroblasts MRC-5 undergoing ageing in vitro. However, a similar 
decrease in low serum-associated G0/Grarrested cells is reversible both in MRC-5 cells and in their SV40-transformed counterparts. Reduced levels 
of ADP-ribosylatable EF-2 could account for the slowing-down of protein synthesis during cell cycle arrest and during cellular ageing in culture. 
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1. INTRODUCTION 
A change in the rate of protein synthesis can have 
wide-ranging effects including those on gene expres- 
sion, on cell physiology and on cell proliferation [1]. 
However, our understanding of the regulation of pro- 
tein synthesis in eukaryotic ells is still very limited. 
One of the main reasons for this is the lack of detailed 
studies on quantitative and qualitative changes in the 
components of the protein synthesis machinery during 
various biological events, such as cell cycle, growth, 
development, ageing and carcinogenesis. 
Although the role of the initiation step in the regula- 
tion of protein synthesis widely recognised as crucial 
[1], several recent studies have indicated that the 
elongation step may also be important in this regard. 
For example, the regulation of protein synthesis at the 
level of elongation has been demonstrated during the 
cell cycle [1], heat shock [2], phorbol ester treatment 
[3], growth factor stimulation [4], transformation [5] 
and ageing [6,7]. However, changes in the amounts and 
activities of various elongation factors (EFs) involved 
in this regulation remain to be documented. Therefore, 
we have undertaken such studies in order to elucidate 
changes in EFs during serial passaging of normal and 
transformed human cells in culture. Previously, we 
have shown that the activity and amounts of active 
EF-lc~, an enzyme which catalyses the binding of 
aminoacyl-tRNA to the A site of the ribosome, under- 
go cell cycle- and age-related changes in normal human 
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fibroblasts and in SV40-transformed cells derived from 
them [7]. 
Here, we report changes in the amounts of ADP- 
ribosylatable EF-2 in serially passaged human fibro- 
blasts undergoing the typical Hayflick aging process in 
culture [8], and in SV40-transformed immortal cells 
1erived from them. EF-2 is the other elongation factor 
which catalyses the translocation of peptidyl-tRNA 
erom the A site to the P site of the ribosome [1]. For 
this purpose, we have used the diphtheria toxin- 
mediated 1:1 stoichiometric ADP-ribosylation assay in 
cell-free extracts in which ADP-ribosylation of the 
diphtamide residue of EF-2 results in the complete in- 
hibition of its activity [9]. Details regarding the sen- 
sitivity, accuracy and advantages of this assay have 
been published elsewhere [10-12]. 
2. MATERIALS AND METHODS 
Normal human embryonic diploid lung fibroblasts, MRC-5, and 
SV40-transformed cells, MRC-5V2, derived from them were used in 
this study. Cells were cultured routinely in Dulbecco's modified 
Eagle's minimum essential medium (DMEM, Biochrom, FRG) con- 
taining 10% fetal calf serum and antibiotics (100 #g/ml streptomycin 
and 100 U/ml penicillin), at 37°C in an atmosphere of 5% COz. In 
vitro lifespan of MRC-5 cells was estimated by calculating the cumu- 
lative population doubling level (PDL) attained on 1:2 serial passag- 
ing, as described before [7]. In this series of experiments, MRC-5 cells 
reached a final PDL 49 during serial passaging, which is here con- 
sidered as 100o70 lifespan. As described by Hayflick [8], cultures were 
considered to be in Phase lI until slowing-down of their growth dur- 
ing the last few passages (Phase Ill) when they leave the cycle irrever- 
sibly. No such change in growth characteristics, however, is observed 
in serially passaged MRC-5V2 cells which continue to proliferate in- 
definitely without showing any signs of ageing. 
For assaying EF-2 in different phases of the growth cycle, cultures 
were considered to be in an exponential phase of growth 20 h after 
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seeding• At this stage, 80-90070 of Phase II MRC-5 cells, less than 
20070 of Phase III MRC-5 cells, and more than 9507o f MRC- 5V2 
cells are capable of entering S phaser of the cell cycle as determined 
by [3H]thymidine labelling and autoradiography [7]. To arrest he 
cells in G0/GL phase of the cell cycle, normal medium was replaced 
with DMEM containing 0.2070 serum for MRC-5 cells and no serum 
for MRC-V2 cells for 72 h. Under these conditions, more than 98070 
of both cell types became growth-arrested, as checked by [3H]thymi- 
dine labelling and autoradiography. 
Methods for both the preparation ofcell-free xtracts and the estima- 
tion of ADP-ribosylatable ADP-ribosylatable EF-2 have been 
described previously [10, 11]. Briefly, triplicate samples of about 
6 × l06 cells each were sonicated in0.5 ml buffer T (25 mM Tris/HCl 
pH 8, 25 mM KCI, 0.5 M NHaCI, 10 mM Mg(CH3COO)2, 10raM 
dithiothreitol, and 3 mM benzamidine) containing 4°7o (w/v) ac- 
tivated charcoal, using a Branson Sonifier Cell Disrupter B15 in 
mode 4, pulse 20% for 20 seconds. The homogenate was shaken 
vigorously in charcoal for 5 rain, in order to remove ndogenous 
NAD. Charcoal was removed by centrifugation 05 000 x g, 20 min) 
and the supernatant was centrifuged again (27000g, 15rain) to 
remove cellular debris and to ensure the removal of all charcoal. All 
operations were performed at 0-4°C. 
The diphtheria toxin-mediated EF-2 assay was performed ina final 
volume of 50 ~l in buffer T containing 2Lf (5 ~tg) of diphtheria toxin 
(a kind gift from Dr. Iver Heron, Statens Seruminstitut, Copen- 
hagen)• Histamine was added to give a final concentration f 0.18 M, 
in order to inhibit he cellular ADP-ribosyltransferases, together with 
1.2 mM [~4C]NAD. The reaction was started by adding the cell-free 
extract and the assay mixture was incubated for 20 rain at 37°C. The 
reaction was stopped by adding 1 ml 10°70 ice-cold TCA, and the acid 
insoluble radioactivity was determined using a Beckmann LS7500 
scintillation counter• The total amounts of soluble protein were deter- 
mined by a modified Bradford method using 3% perchloric acid and 
BSA as the standard [13]. 
3. RESULTS 
The method used in this study measures the total 
amount  of ADP-r ibosylatable EF-2. Previously, we 
have demonstrated a linear relationship between 
amounts  of either purified EF-2 or cell-free extracts 
and the estimated amount  of ADP-r ibosylatable EF-2 
l1 l ,  12]. Since the ADP-r ibosylat ion of the diphthamide 
residue of EF-2 completely abolishes its activity, 
estimating the amount  of ADP-r ibosylatable EF-2 gives 
an indirect measure of the amount  of active EF-2 in 
cell-free extracts. 
There is a decline in the amount  of ADP-r ibo-  
sylatable EF-2 in serially passaged senescent MRC-5 
cells (Fig. 1). Exponential ly growing MRC-5 cultures of 
up to 75070 lifespan completed contained on avarage 
48.3 fmol EF-2//~g protein. Invididual values for three 
separate observations at each t ime-point in l ifespan are 
given in Fig. 1. There was an abrupt decline in the 
amount  of ADP-r ibosylatable EF-2 within the next few 
passages and an average value of 18.3 fmol EF-2//tg 
protein was reached in Phase III senescent cultures with 
more than 80070 lifespan completed (Fig. 1). No further 
change in the amount  of ADP-r ibosylatable EF-2 could 
be observed uring the rest of the l ifespan of MRC-5 
cells in culture. In comparison, exponential ly growing 
SV40-transformed immortal  MRC-SV2 cells contained 
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Fig. 1. Age-related decline in the amount of ADP-ribosylatable EF-2 
(fmol//tg protein) in serially passaged cultures of human fibroblasts, 
MRC-5. Values given on each time-point are of three separate 
observations. 100070 lifespan = PDL 49. 
on average 23.8 fmol EF-2/I~g protein, which did not 
change during serial passaging. 
In order to distinguish age-related changes from 
those due to cell cycle, amounts of ADP-r ibosylatable 
EF-2 during Go/Gl-arrest and after restimulation with 
fresh medium containing 10°70 serum were also deter- 
mined. For this purpose, Phase II young and Phase III 
senescent cultures of MRC-5 cells were compared with 
immortal  MRC-SV2 cells, after serum starvation and 
restimulation. A significant reduction in the amount  of 
ADP-r ibosylatable EF-2 was observed in G0/GI-  
arrested both for Phase II MRC-5 cells (from 50.2 fmol 
to 28.2 fmol) and for immortal  MRC-5V2 cells (from 
23.8 fmol to 11.9 fmol; Fig. 2). After restimulation, 
this change was largely reversed within 20 h (almost 
80070 recovery in MRC-5 cells and 100070 recovery in 
MRC-5V2 cells). In the case of senescent Phase II I  
MRC-5 cells, which already have irreversibly reduced 
amounts  of ADP-r ibosylatable EF-2 due to ageing 
(average 18.3 fmol EF-2; respective values of three 
separate observations were 17.4, 18.3 and 19.4 fmol), 
serum starvation resulted in a further decrease of about 
40070 reaching an average value of 10.9 fmol EF-2/#g 
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Fig. 2. Average amounts of ADP-ribosylatable EF-2 (fmol/~g 
protein) in exponentially growing (Exp.), in low serum-associated 
Go/Gl-arrested (Go), and in 20h restimulated (Stim.) cultures of 
Phase II (7207o lifespan completed), Phase III MRC-5 cells (92°70 
lifespan completed), and SV40-transformed MRC-5V2 cells. 
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protein (individual values for three separate observa- 
tions were 10.1, 10.9 and 11.5 fmol). However, this cell 
cycle-related ecrease in senescent cells was reversible 
after restimulation with serum, although at a much 
slower pace (Fig. 2). 
4. DISCUSSION 
Cell cycle- and age-related changes in the amounts of 
ADP-ribosylatable EF-2 reported in this study fill an 
important gap in our knowledge of the regulation of 
protein synthesis during these processes. Our results 
show that the amounts of ADP-ribosylatable EF-2 are 
reduced significantly during cell cycle-related quies- 
cence and during ageing, two of the conditions in which 
protein synthetic rates have been also observed to 
become low [14,15]. 
The age-related ecline in amounts of ADP-ribo- 
sylatable EF-2 in MRC-5 cells is not attributable simple 
to the fact that the majority of cells in Phase II I  are 
non-dividing. This is because ven though experimen- 
tally induced Go/Gl-arrest reduces the amounts of 
ADP-ribosylatable EF-2, this change is reversible both 
in Phase II cells and in immortal cells when normal 
serum concentration is restored. On the other hand, 
Phase I I I  MRC-5 cells with already reduced amounts of 
ADP-ribosylatable EF-2, show a further reduction due 
to low serum, which is also reversible, although at a 
much slower pace. Similar slow reversion of a cell 
cycle-related decline in senescent MRC-5 cells has been 
observed in the case of EF - la  [7]. This difference in the 
rate of serum-stimulated recovery in young and old 
cells is not surprising, because it is well known that 
there is an age-related ecline in the responsiveness of
old cells to treatment with serum and various growth 
factors [16]. 
Like many other cellular, biochemical and physio- 
logical changes observed in late passage cultures of 
diploid cells [7], the decline in the amount of ADP- 
ribosylatable EF-2 also became apparent only after the 
cells had completed about 75°7o of their proliferative 
lifespan in vitro. Therefore, although we were unable 
to obtain much younger MRC-5 cells of less than 60O7o 
lifespan, due to the limited availability of stocks, it 
does not affect the conclusions derived from the pres- 
ent studies. Thus the reduced amounts of ADP- 
ribosylatable EF-2 in late passage senescent MRC-5 
cells are related to their intrinsic ageing process and 
could well be involved in determining rates of protein 
synthesis in old cells [6, 12, 15]. Transformed MRC- 
5V2 cells, however, differ from normal MRC-5 cells in 
respect of the amount of ADP-ribosylatable EF-2 pres- 
ent in them. Since our assay system estimates only the 
amount of ADP-ribosylatable EF-2, it is not clear 
whether the absolute amounts of EF-2 also vary be- 
tween normal and transformed cells. Our studies are in 
progress to resolve these issues by using antibodies 
against ADP-ribosylated and unribosylated forms of 
EF-2. Furthermore, at present it is also not clear if the 
specific activities of EF-2 vary significantly between 
normal and transformed cells, which may account for 
the differences in their rates of protein synthesis [7, 10], 
Our studies are in progress in this regard. 
The next step in the investigation of the role of EF-2 
during ageing will be determining the levels of mRNA 
and the total content of EF-2, using cDNA probes and 
antibodies, respectively. It also needs to be shown 
whether there is any change in the endogenously ADP- 
ribosylated pool of EF-2 during the cell cycle, transfor- 
mation and ageing. Furthermore, reports of hetero- 
geneity of native forms of phosphorylated and 
ADP-ribosylated EF-2 in rat liver [17], and of changes 
in the relative proportion of phosphorylated and 
unphosphorylated variants of EF-2 during the human 
cell cycle [18] open up new lines of investigation of the 
role of EF-2 in the regulation of protein synthesis. 
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